Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer
The umbrella term "epithelial ovarian cancer" encompasses 5 histologic sub-types with distinct molecular profiles and varying sensitivities to chemotherapy. Historical trials investigating adjuvant management of early-stage disease have not accounted for this heterogeneity. This review examines the evidence guiding the management of stage I and II epithelial ovarian cancer according to histologic sub-type and discusses its application in contemporary modern setting. Areas of interest for future research are highlighted, with an emphasis on the need for more personalized adjuvant therapy using predictive biomarkers and targeted treatments.
